Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing innovative therapies, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage. Durkacz emphasized that this area remains unmet by currently available treatments.
Durkacz also highlighted Quantum BioPharma's commercial alcohol metabolism product, unbuzzd(TM), designed to accelerate blood alcohol metabolism and currently available in the U.S. market. The product is marketed by Unbuzzd Wellness Inc., a company in which Quantum retains a 19.84% ownership stake as of March 31, 2026, and receives royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains 100% rights to develop similar products for pharmaceutical and medical uses.
Looking ahead, Durkacz noted the upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in MS patients following Phase 1 testing in healthy volunteers. Lucid-MS is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. For more information, visit the company's newsroom at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/HURxt.
BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article syndication to over 5,000 outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions.
